Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against vaccinia virus, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against SARS. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases.
パッケージサイズ | 在庫状況 | 単価(税別) |
---|---|---|
25 mg | 約10-14 週間 | ¥ 693,000 |
50 mg | 約10-14 週間 | ¥ 913,500 |
100 mg | 約10-14 週間 | ¥ 1,262,500 |
説明 | EICAR is a drug which acts as an inhibitor of the enzyme IMP dehydrogenase. It is a nucleoside derivative which has both anti-cancer and antiviral effects, and was originally developed for the treatment of leukemia, but was unsuccessful in human clinical trials. It has broad spectrum antiviral effects with activity against vaccinia virus, Semliki forest virus, Junin virus, reovirus, influenza, measles virus and respiratory syncytial virus among others, although it is not active against SARS. This useful spectrum of activity means that EICAR and related derivatives continue to be investigated for the treatment of viral diseases. |
分子量 | 267.24 |
分子式 | C11H13N3O5 |
CAS No. | 118908-07-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EICAR 118908-07-9 Nifuroxazide d4 Inhibitor inhibitor inhibit